Cargando…
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies
Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent dosing schedules supported by preclinical data provide a strategy to reduce frequency and...
Autores principales: | Abbiati, Roberto A., Pourdehnad, Michael, Carrancio, Soraya, Pierce, Daniel W., Kasibhatla, Shailaja, McConnell, Mark, Trotter, Matthew W. B., Loos, Remco, Santini, Cristina C., Ratushny, Alexander V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397660/ https://www.ncbi.nlm.nih.gov/pubmed/34453265 http://dx.doi.org/10.1208/s12248-021-00623-8 |
Ejemplares similares
-
Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies
por: Hatake, Kiyohiko, et al.
Publicado: (2020) -
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022) -
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022) -
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023) -
Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm
por: Romero, Juan P., et al.
Publicado: (2018)